DUBLIN, Calif.--(BUSINESS WIRE)-- SuperGen, Inc. (NASDAQ:SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced that Eisai Inc. today released ...

SAN FRANCISCO, Dec. 8 /PRNewswire/ -- Eisai Corporation of North America today announced data from a Phase II trial evaluating a five-day dosing regimen of Dacogen(R) (decitabine for injection) in ...

DUBLIN, Calif.--(BUSINESS WIRE)-- Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), today announced the pre-publication notice of the Food and Drug Administration (FDA), Oncologic Drugs Advisory Committee ...

MINNEAPOLIS--(BUSINESS WIRE)--Aug. 1, 2006--MGI PHARMA, INC. (Nasdaq:MOGN), a biopharmaceutical company focused in oncology and acute care, today announced that the European Medicines Agency (EMEA) ...

Patients with myeloproliferative neoplasm (MPN) may benefit from this combination treatment if they are in the accelerated or blast phase of the disease. Results from a phase 2 study demonstrated that ...

WOODCLIFF LAKE, N.J.WOODCLIFF LAKE, N.J. — Drugmaker Eisai Inc. said the Food and Drug Administration approved a new, longer dosing regimen of its bone marrow disease treatment Dacogen. Eisai said the ...

The Food and Drug Administration approved the oral combination of Inquovi (Dacogen [decitabine] and cedazuridine) for certain adult patients with myelodysplastic syndromes (MDS). The Food and Drug ...

Dublin-based SuperGen and MGI Pharma Inc. said U.S. regulators approved the companies’ Dacogen treatment, the third drug to win approval for treating a group of fatal blood and bone-marrow disorders.

Johnson & Johnson has garnered expanded approvals from Europe's regulator for two of its cancer treatments. Johnson & Johnson has garnered expanded approvals from Europe’s regulator for two of its ...

Most news items about Astex Pharmaceuticals (NAS: ASTX) focus on the company's profitable drug Dacogen. However, on Monday the company announced movement in its pipeline beyond Dacogen. A phase 1 ...

With approval of Dacogen (decitabine), the injectable drug for myelodysplastic syndromes from MGI Pharma Inc. and SuperGen Inc. expected May 15, analysts continue to weigh the compound’s chances ...

DACOGEN was administered at 20 mg/m 2 as a 1-hour intravenous infusion once daily for five consecutive days, repeated every four weeks, continued as long as the patient derived benefit. Key results ...